Smith & Nephew plc (SNN) Q3 2026 Sales/Trading Call Transcript

Smith & Nephew reported 3.4% underlying revenue growth in Q3 2026, accelerating from Q2. Sports Medicine & ENT remained strong, Wound improved, and Orthopaedics returned to growth, supported by international and emerging markets. U.S. knees and hips remained weak, partly reflecting market softness, while the company said its knee business was affected by the shift toward cementless procedures.

Analysis

The key issue is not the headline growth rate but its composition: strength in Sports Medicine/ENT, Wound and international markets may not offset a persistent U.S. implant disadvantage if the shift toward cementless knees continues. That creates a potential mix problem for SNN: growth in faster-growing areas can support the top line while U.S. knees and hips remain a drag on the segment most exposed to competitive product adoption. Do not assume a margin effect without segment profitability and pricing data.

Over the next 1–3 months, focus on evidence of U.S. knee/hip share stabilization and whether the cementless portfolio is gaining surgeon adoption—not just overall revenue acceleration. Stryker, Zimmer Biomet and Johnson & Johnson are relevant competitive checks, but the excerpt provides no share or product-level evidence to establish who is taking business. International and emerging-market strength is a possible offset, though its durability and profitability are unverified.

The call transcript is truncated before management completes its explanation of the cementless issue and provides no full guidance, margins, or cash-flow detail. That limits conviction. The contrarian risk is that investors may over-credit broad-based recovery from a modest growth acceleration while the U.S. implant weakness persists; conversely, a demonstrated cementless catch-up could make the concern over-discounted. Structural implications over 6–18 months depend on product adoption and surgeon conversion, not this quarter’s aggregate growth alone.

Key Decisions for Investors

• No high-conviction directional trade from this excerpt alone; avoid chasing SNN on the growth acceleration until the full call clarifies guidance, U.S. knee/hip trends, and cementless adoption.
• Set an alert for the complete results materials: verify U.S. knee and hip growth/share indicators, cementless product traction, segment margins, and management’s outlook. These are the missing data needed to distinguish temporary market softness from persistent competitive loss.
• If subsequent disclosures show continued U.S. knee/hip underperformance and no credible cementless recovery, consider a modest relative-value short in SNN versus a diversified medtech peer basket; reassess if SNN reports improving adoption or stabilization in U.S. implants.
• Falsifiers: sustained improvement in U.S. knees and hips, evidence of successful cementless conversion, or guidance that confirms the non-U.S. and adjacent-business growth is translating into durable earnings and cash flow.